Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.

Pharmacogenomics - 1 Jan 2011

Gordon Michael A, Zhang Wu, Yang Dongyun, Iqbal Syma, El-Khouiery Anthony, Nagashima Fumio, Lurje Georg, Labonte Melissa, Wilson Peter, Sherrod Andy, Ladner Robert D, Lenz Heinz-Josef

Abstract excerpt

AIMS: Survival and response rates in metastatic colorectal cancer remain poor, despite advances in drug development. There is increasing evidence to suggest that gender-specific differences may contribute to poor clinical outcome. We tested the hypothesis that genomic profiling of metastatic colorectal cancer is dependent on gender. MATERIALS & METHODS: A total of 152 patients with metastatic colorectal cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Fluorouracil

Share to Neoplasm Metastasis

Share to Organoplatinum Compounds

Share to Oxaliplatin

Share to Sex Characteristics

Source

Open in PubMed Open full text

Identifiers

PMID: 21174620
DOI: 10.2217/pgs.10.163
PMCID: PMC3836679

Genes

EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.PMID 21174620Read ↗

Gender-Related Survival Differences Associated with<i>EGFR</i>Polymorphisms in Metastatic Colon CancerSemantic proximity Read ↗

Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.Semantic proximity Read ↗

Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapySemantic proximity Read ↗

Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.Semantic proximity Read ↗

Gene Regulatory Network Analysis Identifies Sex-Linked Differences in Colon Cancer Drug MetabolismSemantic proximity Read ↗

AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.Semantic proximity Read ↗

Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.Semantic proximity Read ↗

Gender Influences the Class III and V β-Tubulin Ability to Predict Poor Outcome in Colorectal CancerSemantic proximity Read ↗

Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer.Semantic proximity Read ↗

Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.Semantic proximity Read ↗

Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer.Semantic proximity Read ↗

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.